National Institute of Allergy and Infectious Diseases
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

HIV/AIDS
 Understanding
  Quick Facts
  What are HIV and AIDS?
  How HIV Causes AIDS
  Biology of HIV
   Structure of HIV
   HIV Replication Cycle
   HIV Evades the Immune System
   HIV Devastates the Immune System
   HIV Hides from the Immune System
   Clinical Progression of HIV
   Disease Progression Factors
  HIV Risk Factors
  Symptoms
  Testing and Diagnosis
  Treatment
  Prevention
  Publications
 Research


HIV/AIDS

Factors that Affect Disease Progression

Mutations in HIV Co-receptors

Most strains of HIV use a co-receptor molecule called CCR5, in addition to the CD4 molecule, to infect a cell. Other HIV strains use a different co-receptor known as CXCR4 to attack cells. Both receptors enable the virus to enter a cell during the initial stage of HIV infection.

Studies have shown that people infected with HIV who have specific genetic mutations in one of their two copies of the CCR5 gene progress to AIDS slower than people with two normal copies of the CCR5 gene. There are also rare individuals with two mutant copies of the CCR5 gene who appear, in most cases, to be completely protected from HIV infection. Gene mutations in other HIV co-receptors such as CXCR4 also may influence the rate of disease progression.

High Viral Load

HIV patient getting blood drawn.
HIV patient getting blood drawn. Credit: NIAID

People with high levels of HIV in their blood known as viral load, are more likely to progress to AIDS faster than those with lower levels of the virus. In addition, research has shown that the level of HIV in a person’s blood after the first few months of infection, known as the viral set point, also influences the speed of progression to AIDS. Those with higher viral set point are much more likely to get sick faster than those with lower viral set point.

Highly active antiretroviral therapy (HAART), which are potent combinations of three or more antiretroviral drugs belonging to at least two different antiretroviral drug classes, can help lower the viral load and viral set point for those infected with HIV. For many people, HAART delays the progression to AIDS for a prolonged period of time.

back to top

 

Highlights

Washington Post Editorial: A Policy Cocktail for Fighting HIV by Dr. Anthony S. Fauci (Non-government)
April 16, 2009

HHS News Release: U.S. Releases Updated Clinical Guidelines for HIV-Associated Opportunistic Infections
April 16, 2009

Related Links

View a list of links for more information about HIV/AIDS.

See Also

HIV/AIDS News Releases


Highlights

Washington Post Editorial: A Policy Cocktail for Fighting HIV by Dr. Anthony S. Fauci (Non-government)
April 16, 2009

HHS News Release: U.S. Releases Updated Clinical Guidelines for HIV-Associated Opportunistic Infections
April 16, 2009

Related Links

View a list of links for more information about HIV/AIDS.

See Also

HIV/AIDS News Releases